Mitra Emami, MD
Neurology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 25
- 5 carriers
- Offices
- 2
Offices
2 locations
Hospitals listed: 059765 · El Camino Health · Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
25 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Emami’s office at (408) 358-6525 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
25 of 25 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$150,086
Medicare paid this office $150,086 for 370 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 74 | $41,396 | $168 |
| Long return visit (40+ min) | 130 | $30,617 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $18,064 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 118 | $16,411 | $138 |
| New patient visit (60+ min) | 71 | $12,289 | $173 |
See all 8 services
| Critical care, first 30-74 minutes | 74 | $41,396 | $168 |
| Long return visit (40+ min) | 130 | $30,617 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $18,064 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 118 | $16,411 | $138 |
| New patient visit (60+ min) | 71 | $12,289 | $173 |
| Return visit (30+ min) | 51 | $7,100 | $97 |
| Measurement of brain wave activity (eeg), awake and drowsy | 36 | $2,068 | $47 |
| Short return visit (20+ min) | 13 | $1,251 | $63 |
Who their Medicare patients are
370 Original Medicare patients in 2024. Average age 78 · Under 65 4% · 85 and older 22% · Women 55% · Also on Medicaid 23% · Health risk score 1.70. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Stroke 50% · Coronary heart disease 48% · Diabetes 40% · Dementia 36% · Chronic kidney disease 35% · Atrial fibrillation 32% · Depression 30% · Heart failure 25% · Cancer 18% · COPD 14%.
The office billed $268,675, Medicare allowed $198,954 and paid $150,086; for 4,225 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 370 | 4,225 | 78 | 1.70 | $268,675 | $150,086 |
| 2023 | 400 | 3,727 | 78 | 1.59 | $235,861 | $144,982 |
| 2022 | 347 | 3,168 | 77 | 1.99 | $194,909 | $118,711 |
| 2021 | 333 | 3,392 | 77 | 1.64 | $198,835 | $123,902 |
| 2020 | 284 | 2,587 | 77 | 1.72 | $138,665 | $76,479 |
| 2019 | 438 | 3,168 | 78 | 1.64 | $222,844 | $135,632 |
| 2018 | 452 | 2,743 | 79 | 1.77 | $209,606 | $124,994 |
| 2017 | 448 | 4,017 | 78 | 1.62 | $263,236 | $151,260 |
| 2016 | 451 | 3,058 | 79 | 1.63 | $232,119 | $136,052 |
| 2015 | 405 | 2,831 | 77 | 1.69 | $231,247 | $132,133 |
| 2014 | 406 | 2,137 | 77 | 1.43 | $195,114 | $117,317 |
| 2013 | 409 | 2,467 | 77 | 1.56 | $211,293 | $122,552 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Critical care, first 30-74 minutes | 71 | $30,448 | $188 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 149 | $23,036 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 119 | $20,504 | $107 |
| Long return visit (40+ min) | 83 | $18,887 | $149 |
| New patient visit (60+ min) | 86 | $17,033 | $198 |
| Return visit (30+ min) | 79 | $11,173 | $103 |
| Short return visit (20+ min) | 19 | $1,984 | $76 |
| Measurement of brain wave activity (eeg), awake and drowsy | 34 | $1,947 | $51 |
2022: 8 services
| Critical care, first 30-74 minutes | 72 | $33,213 | $193 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 123 | $21,883 | $176 |
| Long return visit (40+ min) | 78 | $15,616 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $12,970 | $92 |
| Return visit (30+ min) | 71 | $10,191 | $99 |
| New patient visit (60+ min) | 24 | $4,917 | $205 |
| Short return visit (20+ min) | 20 | $2,255 | $70 |
| Measurement of brain wave activity (eeg), awake and drowsy | 34 | $1,799 | $53 |
2021: 8 services
| Critical care, first 30-74 minutes | 55 | $31,557 | $197 |
| Long return visit (40+ min) | 76 | $16,630 | $154 |
| Return visit (30+ min) | 105 | $16,506 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 91 | $16,490 | $179 |
| New patient visit (60+ min) | 64 | $12,649 | $198 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $8,690 | $93 |
| Short return visit (20+ min) | 40 | $3,811 | $67 |
| Measurement of brain wave activity (eeg), awake and drowsy | 34 | $1,893 | $53 |
2020: 9 services
| Critical care, first 30-74 minutes | 38 | $16,425 | $189 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 86 | $15,093 | $172 |
| Return visit (30+ min) | 111 | $12,784 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $8,799 | $91 |
| New patient visit (45+ min) | 30 | $4,096 | $137 |
| Short return visit (20+ min) | 51 | $3,989 | $61 |
| Long return visit (40+ min) | 11 | $1,676 | $129 |
| Measurement of brain wave activity (eeg), awake and drowsy | 25 | $1,288 | $52 |
| New patient visit (30+ min) | 11 | $894 | $81 |
2019: 7 services
| Return visit (30+ min) | 216 | $38,307 | $96 |
| Critical care, first 30-74 minutes | 67 | $36,510 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $19,081 | $180 |
| New patient visit (45+ min) | 85 | $12,428 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $9,672 | $93 |
| Long return visit (40+ min) | 29 | $4,568 | $127 |
| Measurement of brain wave activity (eeg), awake and drowsy | 21 | $1,171 | $53 |
2018: 7 services
| Return visit (30+ min) | 195 | $33,448 | $91 |
| Critical care, first 30-74 minutes | 54 | $25,283 | $190 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 127 | $22,918 | $176 |
| New patient visit (45+ min) | 90 | $12,962 | $144 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $10,443 | $91 |
| Long return visit (40+ min) | 34 | $4,985 | $125 |
| Measurement of brain wave activity (eeg), awake and drowsy | 35 | $1,805 | $52 |
2017: 7 services
| Return visit (30+ min) | 215 | $37,572 | $92 |
| Critical care, first 30-74 minutes | 53 | $36,743 | $190 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 136 | $24,446 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 103 | $15,765 | $91 |
| New patient visit (45+ min) | 89 | $12,816 | $144 |
| Long return visit (40+ min) | 26 | $3,601 | $124 |
| Measurement of brain wave activity (eeg), awake and drowsy | 44 | $2,402 | $50 |
2016: 8 services
| Return visit (30+ min) | 234 | $41,804 | $92 |
| Critical care, first 30-74 minutes | 48 | $24,656 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 100 | $19,273 | $180 |
| New patient visit (45+ min) | 120 | $17,294 | $144 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $13,148 | $93 |
| Long return visit (40+ min) | 30 | $4,304 | $127 |
| Measurement of brain wave activity (eeg), awake and drowsy | 30 | $1,601 | $52 |
| Short return visit (20+ min) | 12 | $794 | $66 |
2015: 7 services
| Return visit (30+ min) | 233 | $44,950 | $95 |
| Critical care, first 30-74 minutes | 43 | $21,799 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 107 | $21,185 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 77 | $11,736 | $93 |
| New patient visit (45+ min) | 71 | $10,459 | $147 |
| Long return visit (40+ min) | 30 | $4,482 | $128 |
| Measurement of brain wave activity (eeg), awake and drowsy | 31 | $1,839 | $53 |
2014: 8 services
| Return visit (30+ min) | 235 | $43,293 | $93 |
| Critical care, first 30-74 minutes | 36 | $17,983 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $16,728 | $180 |
| New patient visit (45+ min) | 96 | $14,019 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $9,334 | $92 |
| Long return visit (40+ min) | 12 | $1,686 | $130 |
| Short return visit (20+ min) | 17 | $1,226 | $65 |
| Measurement of brain wave activity (eeg), awake and drowsy | 16 | $890 | $52 |
2013: 9 services
| Return visit (30+ min) | 217 | $40,163 | $89 |
| Critical care, first 30-74 minutes | 45 | $21,168 | $191 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 100 | $18,724 | $175 |
| New patient visit (45+ min) | 82 | $11,666 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $7,659 | $90 |
| Long return visit (40+ min) | 38 | $5,331 | $124 |
| New patient visit (60+ min) | 12 | $2,111 | $176 |
| Critical care, each additional 30 minutes | 14 | $1,340 | $96 |
| Measurement of brain wave activity (eeg), awake and drowsy | 12 | $616 | $51 |
Medicaid work
$160 in 2022
Medicaid paid $160 for 12 billed services this clinician did in 2022, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| 1ST HOSP IP/OBS HIGH 75 | 12 | $160 |
| 2022 | 12 | 1 | 12 | $160 |
Drugs they prescribed that Part D paid
$272,527
Pharmacies billed $272,527 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
946 generic and fewer than 11 brand-name prescriptions · $272,527 in drug cost · 41 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vumerity | None | 12 | $103,630 | $8,636 |
| Namzaric | None | 26 | $29,736 | $1,144 |
| Nuedexta | None | 12 | $18,320 | $1,527 |
| Rytary | Parkinson's | 19 | $15,435 | $812 |
| Qulipta | None | 13 | $14,030 | $1,079 |
See all 33 drugs
| Vumerity | None | 12 | $103,630 | $8,636 |
| Namzaric | None | 26 | $29,736 | $1,144 |
| Nuedexta | None | 12 | $18,320 | $1,527 |
| Rytary | Parkinson's | 19 | $15,435 | $812 |
| Qulipta | None | 13 | $14,030 | $1,079 |
| Divalproex Sodium Er | None | 52 | $3,382 | $65 |
| Rivastigmine | None | 17 | $2,471 | $145 |
| Memantine | None | 102 | $1,983 | $19 |
| Carbidopa-Levodopa | None | 71 | $1,867 | $26 |
| Mycophenolate Mofetil | None | 12 | $1,485 | $124 |
| Levetiracetam | None | 30 | $1,333 | $44 |
| Gabapentin | None | 68 | $1,330 | $20 |
| Lacosamide | None | 23 | $967 | $42 |
| Divalproex | None | 12 | $901 | $75 |
| Oxcarbazepine | None | 18 | $722 | $40 |
| Donepezil | None | 67 | $714 | $11 |
| Quetiapine | None | 36 | $698 | $19 |
| Levetiracetam Er | None | 13 | $591 | $45 |
| Memantine Hcl Er | None | 11 | $564 | $51 |
| Pregabalin | None | 25 | $526 | $21 |
| Carbidopa-Levodopa Er | None | 12 | $482 | $40 |
| Duloxetine | None | 12 | $364 | $30 |
| Primidone | None | 14 | $357 | $26 |
| Carbamazepine | None | 13 | $326 | $25 |
| Escitalopram | None | 36 | $280 | $8 |
| Bupropion Xl | None | 33 | $275 | $8 |
| Mirtazapine | None | 22 | $249 | $11 |
| Trazodone | None | 19 | $166 | $9 |
| Sertraline | None | 43 | $147 | $3 |
| Clonazepam | None | 21 | $128 | $6 |
| Vitamin D2 | None | 12 | $38 | $3 |
| Clopidogrel | None | 23 | $33 | $1 |
| Atorvastatin | None | 11 | $10 | $1 |
Year by year
| 2024 | 1,077 | 159 | None | None | $272,527 |
| 2023 | 888 | 151 | None | 12% | $197,943 |
| 2022 | 935 | 139 | 0% (0) | 16% | $197,603 |
| 2021 | 1,301 | 170 | None | 17% | $238,707 |
| 2020 | 1,388 | 170 | None | None | $230,542 |
| 2019 | 1,651 | 232 | None | 19% | $393,348 |
| 2018 | 1,714 | 209 | None | None | $429,388 |
| 2017 | 1,729 | 193 | None | None | $312,645 |
| 2016 | 1,779 | 217 | None | None | $338,330 |
| 2015 | 2,043 | 219 | 2% (35) | 23% | $310,141 |
| 2014 | 2,278 | 220 | 3% (62) | 25% | $413,330 |
| 2013 | 2,085 | 210 | 2% (31) | 30% | $558,794 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Namzaric | None | 24 | $27,343 | $1,139 |
| Nurtec Odt | None | 13 | $23,072 | $1,775 |
| Rytary | Parkinson's | 22 | $21,163 | $962 |
| Lacosamide | None | 38 | $6,458 | $170 |
| Rivastigmine | None | 17 | $5,987 | $352 |
| Divalproex Sodium Er | None | 45 | $4,053 | $90 |
| Memantine | None | 76 | $3,692 | $49 |
| Mycophenolate Mofetil | None | 13 | $3,609 | $278 |
| Carbidopa-Levodopa | None | 62 | $2,671 | $43 |
| Gabapentin | None | 57 | $2,054 | $36 |
| Memantine Hcl Er | None | 16 | $1,713 | $107 |
| Divalproex | None | 11 | $1,599 | $145 |
| Quetiapine | None | 25 | $731 | $29 |
| Donepezil | None | 45 | $635 | $14 |
| Carbamazepine | None | 12 | $591 | $49 |
| Pregabalin | None | 24 | $576 | $24 |
| Escitalopram | None | 30 | $480 | $16 |
| Duloxetine | None | 11 | $407 | $37 |
| Mirtazapine | None | 32 | $383 | $12 |
| Topiramate | None | 16 | $359 | $22 |
| Ziprasidone | None | 12 | $321 | $27 |
| Levetiracetam | None | 11 | $306 | $28 |
| Risperidone | None | 12 | $136 | $11 |
| Lorazepam | None | 11 | $129 | $12 |
| Clopidogrel | None | 17 | $105 | $6 |
2022: 25 drugs
| Nuedexta | None | 35 | $64,866 | $1,853 |
| Vimpat | None | 31 | $24,694 | $797 |
| Rytary | Parkinson's | 19 | $15,653 | $824 |
| Namzaric | None | 21 | $15,451 | $736 |
| Lacosamide | None | 27 | $10,092 | $374 |
| Divalproex Sodium Er | None | 36 | $7,659 | $213 |
| Rivastigmine | None | 33 | $6,948 | $211 |
| Memantine | None | 110 | $5,828 | $53 |
| Memantine Hcl Er | None | 12 | $4,460 | $372 |
| Divalproex | None | 18 | $2,258 | $125 |
| Gabapentin | None | 60 | $1,735 | $29 |
| Carbidopa-Levodopa | None | 42 | $1,709 | $41 |
| Donepezil | None | 60 | $902 | $15 |
| Quetiapine | None | 19 | $847 | $45 |
| Pregabalin | None | 17 | $809 | $48 |
| Carbamazepine | None | 12 | $620 | $52 |
| Duloxetine | None | 15 | $431 | $29 |
| Escitalopram | None | 28 | $419 | $15 |
| Ziprasidone | None | 13 | $407 | $31 |
| Celecoxib | None | 12 | $325 | $27 |
| Atorvastatin | None | 20 | $257 | $13 |
| Mirtazapine | None | 25 | $247 | $10 |
| Sertraline | None | 30 | $166 | $6 |
| Trazodone | None | 12 | $81 | $7 |
| Clonazepam | None | 13 | $80 | $6 |
2021: 31 drugs
| Nuedexta | 44 | $69,739 | $1,585 |
| Vimpat | 46 | $35,076 | $763 |
| Namzaric | 42 | $34,805 | $829 |
| Memantine Hcl Er | 31 | $7,453 | $240 |
| Rivastigmine | 35 | $7,437 | $212 |
| Namenda Xr | 11 | $6,433 | $585 |
| Memantine | 129 | $5,196 | $40 |
| Divalproex Sodium Er | 47 | $5,153 | $110 |
| Pyridostigmine Bromide Er | 12 | $4,157 | $346 |
| Gabapentin | 91 | $2,468 | $27 |
| Carbidopa-Levodopa | 42 | $1,737 | $41 |
| Donepezil | 131 | $1,522 | $12 |
| Oxcarbazepine | 24 | $1,100 | $46 |
| Divalproex | 23 | $992 | $43 |
| Celecoxib | 16 | $923 | $58 |
| Topiramate | 18 | $870 | $48 |
| Ziprasidone | 14 | $831 | $59 |
| Pregabalin | 18 | $802 | $45 |
| Levetiracetam | 29 | $690 | $24 |
| Duloxetine | 15 | $598 | $40 |
| Ropinirole | 12 | $500 | $42 |
| Sertraline | 74 | $486 | $7 |
| Escitalopram | 25 | $465 | $19 |
| Carbamazepine | 13 | $465 | $36 |
| Mirtazapine | 37 | $374 | $10 |
| Atorvastatin | 23 | $300 | $13 |
| Propranolol | 15 | $241 | $16 |
| Quetiapine | 23 | $239 | $10 |
| Risperidone | 16 | $185 | $12 |
| Clonazepam | 12 | $69 | $6 |
| Trazodone | 15 | $62 | $4 |
2020: 33 drugs
| Nuedexta | None | 38 | $58,178 | $1,531 |
| Namzaric | None | 61 | $45,016 | $738 |
| Vimpat | None | 27 | $21,171 | $784 |
| Namenda Xr | None | 23 | $14,560 | $633 |
| Aimovig | Migraine | 12 | $10,344 | $862 |
| Rivastigmine | None | 36 | $8,887 | $247 |
| Memantine Hcl Er | None | 32 | $7,210 | $225 |
| Memantine | None | 153 | $4,215 | $28 |
| Divalproex Sodium Er | None | 57 | $3,823 | $67 |
| Ziprasidone | None | 36 | $3,585 | $100 |
| Gabapentin | None | 106 | $3,069 | $29 |
| Donepezil | None | 123 | $1,468 | $12 |
| Carbidopa-Levodopa Er | None | 18 | $1,456 | $81 |
| Divalproex | None | 22 | $1,377 | $63 |
| Oxcarbazepine | None | 24 | $1,173 | $49 |
| Carbidopa-Levodopa | None | 33 | $1,066 | $32 |
| Pregabalin | None | 17 | $751 | $44 |
| Sertraline | None | 79 | $738 | $9 |
| Ropinirole | None | 17 | $670 | $39 |
| Topiramate | None | 16 | $645 | $40 |
| Quetiapine | None | 30 | $425 | $14 |
| Mirtazapine | None | 32 | $409 | $13 |
| Levetiracetam | None | 24 | $371 | $15 |
| Duloxetine | None | 17 | $330 | $19 |
| Propranolol | None | 14 | $277 | $20 |
| Carbamazepine | None | 12 | $260 | $22 |
| Fluoxetine | None | 14 | $238 | $17 |
| Risperidone | None | 13 | $229 | $18 |
| Atorvastatin | None | 20 | $220 | $11 |
| Clonazepam | None | 30 | $164 | $5 |
| Escitalopram | None | 20 | $143 | $7 |
| Lorazepam | None | 11 | $111 | $10 |
| Trazodone | None | 21 | $103 | $5 |
2019: 35 drugs
| Namzaric | 123 | $73,500 | $598 |
| Nuedexta | 33 | $53,715 | $1,628 |
| Vimpat | 43 | $34,333 | $798 |
| Rivastigmine | 34 | $13,641 | $401 |
| Namenda Xr | 17 | $9,812 | $577 |
| Eliquis | 14 | $8,442 | $603 |
| Memantine Hcl Er | 23 | $7,065 | $307 |
| Pyridostigmine Bromide Er | 11 | $6,808 | $619 |
| Divalproex Sodium Er | 75 | $6,451 | $86 |
| Memantine | 135 | $4,329 | $32 |
| Gabapentin | 99 | $3,449 | $35 |
| Carbidopa-Levodopa Er | 34 | $2,976 | $88 |
| Donepezil | 184 | $2,121 | $12 |
| Entacapone | 11 | $1,696 | $154 |
| Ziprasidone | 23 | $1,361 | $59 |
| Oxcarbazepine | 24 | $1,159 | $48 |
| Carbidopa-Levodopa | 36 | $1,138 | $32 |
| Ropinirole | 35 | $1,060 | $30 |
| Sertraline | 110 | $961 | $9 |
| Duloxetine | 18 | $898 | $50 |
| Divalproex | 13 | $842 | $65 |
| Levetiracetam | 38 | $645 | $17 |
| Quetiapine | 31 | $610 | $20 |
| Escitalopram | 21 | $590 | $28 |
| Pregabalin | 13 | $496 | $38 |
| Mirtazapine | 31 | $418 | $13 |
| Propranolol | 12 | $374 | $31 |
| Primidone | 15 | $339 | $23 |
| Fluoxetine | 15 | $255 | $17 |
| Pravastatin | 11 | $231 | $21 |
| Clonazepam | 39 | $230 | $6 |
| Sumatriptan | 11 | $213 | $19 |
| Trazodone | 33 | $210 | $6 |
| Atorvastatin | 21 | $208 | $10 |
| Prednisone | 18 | $175 | $10 |
2018: 35 drugs
| Nuedexta | 98 | $113,377 | $1,157 |
| Namzaric | 96 | $52,938 | $551 |
| Vimpat | 41 | $33,146 | $808 |
| Namenda Xr | 24 | $15,536 | $647 |
| Rivastigmine | 34 | $13,842 | $407 |
| Divalproex Sodium Er | 67 | $7,493 | $112 |
| Relpax | 12 | $7,198 | $600 |
| Memantine | 136 | $6,938 | $51 |
| Memantine Hcl Er | 14 | $5,810 | $415 |
| Gabapentin | 97 | $3,217 | $33 |
| Donepezil | 235 | $2,524 | $11 |
| Rivastigmine | 19 | $2,177 | $115 |
| Carbidopa-Levodopa Er | 20 | $1,994 | $100 |
| Oxcarbazepine | 28 | $1,769 | $63 |
| Ropinirole | 34 | $1,173 | $35 |
| Levetiracetam Er | 11 | $1,115 | $101 |
| Quetiapine | 76 | $1,020 | $13 |
| Sertraline | 99 | $828 | $8 |
| Carbidopa-Levodopa | 44 | $777 | $18 |
| Duloxetine | 11 | $443 | $40 |
| Atorvastatin | 26 | $443 | $17 |
| Levetiracetam | 28 | $394 | $14 |
| Propranolol | 16 | $356 | $22 |
| Primidone | 19 | $300 | $16 |
| Sumatriptan | 14 | $251 | $18 |
| Simvastatin | 18 | $232 | $13 |
| Topiramate | 15 | $220 | $15 |
| Escitalopram | 17 | $220 | $13 |
| Bupropion Hcl Sr | 12 | $207 | $17 |
| Prednisone | 17 | $191 | $11 |
| Fluoxetine | 15 | $179 | $12 |
| Trazodone | 38 | $178 | $5 |
| Clopidogrel | 15 | $166 | $11 |
| Clonazepam | 36 | $157 | $4 |
| Mirtazapine | 13 | $122 | $9 |
2017: 34 drugs
| Nuedexta | 78 | $65,629 | $841 |
| Namzaric | 91 | $44,956 | $494 |
| Vimpat | 49 | $41,497 | $847 |
| Namenda Xr | 61 | $30,542 | $501 |
| Rivastigmine | 28 | $10,316 | $368 |
| Divalproex Sodium Er | 63 | $9,494 | $151 |
| Exelon | 12 | $7,115 | $593 |
| Memantine | 125 | $6,027 | $48 |
| Gabapentin | 121 | $3,188 | $26 |
| Donepezil | 174 | $1,969 | $11 |
| Carbidopa-Levodopa Er | 23 | $1,730 | $75 |
| Oxcarbazepine | 28 | $1,682 | $60 |
| Carbidopa-Levodopa | 64 | $1,569 | $25 |
| Levetiracetam Er | 20 | $1,567 | $78 |
| Duloxetine | 29 | $954 | $33 |
| Ropinirole | 24 | $950 | $40 |
| Quetiapine | 60 | $720 | $12 |
| Levetiracetam | 39 | $670 | $17 |
| Sertraline | 71 | $595 | $8 |
| Lamotrigine | 12 | $462 | $38 |
| Venlafaxine Hcl Er | 27 | $411 | $15 |
| Bupropion Hcl Sr | 24 | $379 | $16 |
| Atorvastatin | 28 | $322 | $12 |
| Fluoxetine | 33 | $278 | $8 |
| Escitalopram | 24 | $276 | $12 |
| Amitriptyline | 16 | $245 | $15 |
| Trazodone | 43 | $222 | $5 |
| Clonazepam | 57 | $207 | $4 |
| Mirtazapine | 18 | $131 | $7 |
| Topiramate | 11 | $127 | $12 |
| Simvastatin | 22 | $123 | $6 |
| Clopidogrel | 14 | $79 | $6 |
| Prednisone | 18 | $78 | $4 |
| Zolpidem | 11 | $45 | $4 |
2016: 40 drugs
| Vimpat | 51 | $43,245 | $848 |
| Nuedexta | 54 | $38,090 | $705 |
| Namenda Xr | 45 | $25,802 | $573 |
| Rivastigmine | 42 | $14,242 | $339 |
| Exelon | 18 | $13,230 | $735 |
| Lyrica | 16 | $10,795 | $675 |
| Eliquis | 14 | $7,435 | $531 |
| Divalproex Sodium Er | 43 | $6,309 | $147 |
| Memantine | 114 | $6,280 | $55 |
| Namzaric | 14 | $5,719 | $408 |
| Gabapentin | 162 | $4,031 | $25 |
| Donepezil | 231 | $3,480 | $15 |
| Rivastigmine | 11 | $2,952 | $268 |
| Levetiracetam Er | 30 | $2,464 | $82 |
| Carbidopa-Levodopa Er | 36 | $2,388 | $66 |
| Oxcarbazepine | 25 | $1,842 | $74 |
| Carbidopa-Levodopa | 67 | $1,651 | $25 |
| Celecoxib | 15 | $1,414 | $94 |
| Duloxetine | 27 | $1,190 | $44 |
| Quetiapine | 53 | $930 | $18 |
| Levetiracetam | 51 | $914 | $18 |
| Sertraline | 83 | $613 | $7 |
| Ropinirole | 17 | $570 | $34 |
| Lamotrigine | 32 | $538 | $17 |
| Eszopiclone | 11 | $506 | $46 |
| Venlafaxine Hcl Er | 26 | $421 | $16 |
| Amitriptyline | 22 | $320 | $15 |
| Rizatriptan | 12 | $268 | $22 |
| Atorvastatin | 21 | $258 | $12 |
| Fluoxetine | 30 | $219 | $7 |
| Primidone | 11 | $184 | $17 |
| Verapamil Er | 17 | $180 | $11 |
| Clopidogrel | 30 | $175 | $6 |
| Clonazepam | 45 | $171 | $4 |
| Escitalopram | 25 | $146 | $6 |
| Topiramate | 12 | $143 | $12 |
| Mirtazapine | 15 | $143 | $10 |
| Trazodone | 33 | $126 | $4 |
| Prednisone | 16 | $110 | $7 |
| Simvastatin | 22 | $75 | $3 |
2015: 47 drugs
| Namenda Xr | 146 | $59,864 | $410 |
| Exelon | 62 | $30,213 | $487 |
| Vimpat | 40 | $25,614 | $640 |
| Lamictal Xr | 16 | $18,767 | $1,173 |
| Lyrica | 34 | $18,094 | $532 |
| Lamotrigine Er | 13 | $11,739 | $903 |
| Namenda | 39 | $10,504 | $269 |
| Eliquis | 18 | $8,162 | $453 |
| Nuedexta | 11 | $7,427 | $675 |
| Rivastigmine | 16 | $6,267 | $392 |
| Carbidopa-Levodopa Er | 80 | $5,053 | $63 |
| Gabapentin | 143 | $4,854 | $34 |
| Divalproex Sodium Er | 40 | $4,751 | $119 |
| Donepezil | 254 | $4,171 | $16 |
| Xarelto | 11 | $3,600 | $327 |
| Memantine | 30 | $3,581 | $119 |
| Duloxetine | 25 | $2,953 | $118 |
| Levetiracetam Er | 26 | $2,433 | $94 |
| Celecoxib | 29 | $2,424 | $84 |
| Carbidopa-Levodopa | 74 | $2,199 | $30 |
| Carbamazepine Er | 11 | $1,533 | $139 |
| Quetiapine | 51 | $1,251 | $25 |
| Oxcarbazepine | 24 | $1,217 | $51 |
| Eszopiclone | 11 | $914 | $83 |
| Clonazepam | 58 | $912 | $16 |
| Carbamazepine | 13 | $863 | $66 |
| Sertraline | 85 | $688 | $8 |
| Venlafaxine Hcl Er | 36 | $600 | $17 |
| Levetiracetam | 20 | $578 | $29 |
| Ropinirole | 22 | $576 | $26 |
| Lamotrigine | 50 | $522 | $10 |
| Amitriptyline | 31 | $437 | $14 |
| Atorvastatin | 31 | $425 | $14 |
| Primidone | 12 | $342 | $29 |
| Escitalopram | 21 | $317 | $15 |
| Mirtazapine | 27 | $262 | $10 |
| Trazodone | 41 | $246 | $6 |
| Levothyroxine | 11 | $220 | $20 |
| Fluoxetine | 31 | $218 | $7 |
| Clopidogrel | 29 | $215 | $7 |
| Simvastatin | 21 | $181 | $9 |
| Prednisone | 18 | $149 | $8 |
| Hydrocodone-Acetaminophen | 12 | $147 | $12 |
| Topiramate | 28 | $143 | $5 |
| Propranolol | 13 | $127 | $10 |
| Citalopram Hbr | 17 | $120 | $7 |
| Tramadol | 12 | $98 | $8 |
2014: 45 drugs
| Namenda Xr | 150 | $51,943 | $346 |
| Exelon | 102 | $41,889 | $411 |
| Namenda | 120 | $38,339 | $319 |
| Lyrica | 31 | $16,211 | $523 |
| Celebrex | 37 | $9,790 | $265 |
| Lamotrigine Er | 20 | $9,220 | $461 |
| Vimpat | 12 | $8,192 | $683 |
| Divalproex Sodium Er | 63 | $7,731 | $123 |
| Eliquis | 15 | $6,489 | $433 |
| Donepezil | 292 | $5,369 | $18 |
| Carbidopa-Levodopa Er | 94 | $5,091 | $54 |
| Levetiracetam Er | 38 | $4,841 | $127 |
| Gabapentin | 112 | $4,490 | $40 |
| Rivastigmine | 22 | $4,276 | $194 |
| Cymbalta | 11 | $3,350 | $305 |
| Carbidopa-Levodopa | 70 | $3,183 | $45 |
| Duloxetine | 15 | $2,885 | $192 |
| Zolmitriptan | 22 | $2,113 | $96 |
| Quetiapine | 80 | $1,539 | $19 |
| Sertraline | 140 | $1,261 | $9 |
| Ropinirole | 30 | $1,238 | $41 |
| Venlafaxine Hcl Er | 25 | $1,004 | $40 |
| Clonazepam | 42 | $901 | $21 |
| Bupropion Xl | 20 | $846 | $42 |
| Lamotrigine | 75 | $813 | $11 |
| Levetiracetam | 26 | $766 | $29 |
| Clopidogrel | 39 | $712 | $18 |
| Oxcarbazepine | 16 | $678 | $42 |
| Carbamazepine | 13 | $572 | $44 |
| Hydrocodone-Acetaminophen | 20 | $558 | $28 |
| Escitalopram | 32 | $427 | $13 |
| Mirtazapine | 32 | $422 | $13 |
| Fluoxetine | 27 | $421 | $16 |
| Atorvastatin | 17 | $346 | $20 |
| Ketorolac Tromethamine | 16 | $328 | $21 |
| Amitriptyline | 20 | $298 | $15 |
| Levothyroxine | 23 | $290 | $13 |
| Verapamil Er | 13 | $269 | $21 |
| Tramadol | 22 | $223 | $10 |
| Primidone | 13 | $203 | $16 |
| Simvastatin | 17 | $188 | $11 |
| Citalopram Hbr | 17 | $182 | $11 |
| Promethazine | 11 | $130 | $12 |
| Prednisone | 15 | $117 | $8 |
| Propranolol | 15 | $71 | $5 |
2013: 38 drugs
| Gamunex-C | Immune globulin | 18 | $296,572 | $16,476 |
| Namenda | None | 228 | $71,480 | $314 |
| Exelon | None | 154 | $53,120 | $345 |
| Cymbalta | None | 58 | $21,903 | $378 |
| Lyrica | None | 30 | $13,877 | $463 |
| Quetiapine | None | 89 | $7,323 | $82 |
| Vimpat | None | 11 | $6,044 | $549 |
| Lidoderm | None | 12 | $5,570 | $464 |
| Divalproex Sodium Er | None | 68 | $5,179 | $76 |
| Gabapentin | None | 114 | $5,147 | $45 |
| Donepezil | None | 269 | $4,735 | $18 |
| Carbidopa-Levodopa Er | None | 86 | $4,171 | $49 |
| Carbidopa-Levodopa | None | 93 | $4,118 | $44 |
| Rivastigmine | None | 16 | $3,369 | $211 |
| Levetiracetam | None | 58 | $2,223 | $38 |
| Celebrex | None | 11 | $1,913 | $174 |
| Galantamine Hbr | None | 13 | $1,769 | $136 |
| Sertraline | None | 109 | $1,137 | $10 |
| Clopidogrel | None | 26 | $913 | $35 |
| Bupropion Xl | None | 18 | $907 | $50 |
| Lamotrigine | None | 55 | $708 | $13 |
| Venlafaxine Hcl Er | None | 20 | $705 | $35 |
| Primidone | None | 25 | $664 | $27 |
| Naratriptan | None | 11 | $648 | $59 |
| Atorvastatin | None | 13 | $585 | $45 |
| Oxcarbazepine | None | 13 | $519 | $40 |
| Clonazepam | None | 27 | $494 | $18 |
| Mirtazapine | None | 29 | $449 | $15 |
| Ketorolac Tromethamine | None | 22 | $233 | $11 |
| Carbamazepine | None | 12 | $218 | $18 |
| Topiramate | None | 12 | $199 | $17 |
| Levothyroxine | None | 17 | $170 | $10 |
| Promethazine | None | 12 | $154 | $13 |
| Simvastatin | None | 18 | $147 | $8 |
| Hydrocodone-Acetaminophen | None | 11 | $141 | $13 |
| Prednisone | None | 22 | $112 | $5 |
| Trazodone | None | 17 | $74 | $4 |
| Amitriptyline | None | 14 | $71 | $5 |
Money from drug and device companies
$1,656 in 2025
| 2025 | 21 | 74 | None | $1,656 |
| 2024 | 23 | 128 | None | $2,667 |
| 2023 | 21 | 86 | None | $1,798 |
| 2022 | 18 | 80 | None | $1,552 |
| 2021 | 24 | 147 | None | $2,246 |
| 2020 | 17 | 61 | None | $994 |
| 2019 | 21 | 65 | $17 | $1,212 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Catalyst Pharmaceuticals | Firdapse | $263 | 17 payments
|
| Alexion Pharmaceuticals | Ultomiris | $167 | 6 payments
|
| Eisai | Leqembi | $162 | 7 payments
|
| Neurelis | Valtoco | $140 | 6 payments
|
| Teva Pharmaceuticals USA | Ajovy | $123 | 4 payments
|
| Pfizer | Nurtec Odt | $120 | 5 payments
|
See all 74 published payments
| Neurelis | Meals · 2025-12-17 | Valtoco | $24 |
| Catalyst Pharmaceuticals | Meals · 2025-12-16 | Firdapse | $14 |
| Catalyst Pharmaceuticals | Meals · 2025-12-16 | Firdapse | $11 |
| Alexion Pharmaceuticals | Meals · 2025-12-10 | Ultomiris | $25 |
| SK Life Science | Meals · 2025-11-20 | None | $19 |
| Amgen | Meals · 2025-11-18 | Uplizna | $23 |
| Abbvie | Meals · 2025-11-17 | Ubrelvy | $19 |
| Neurelis | Meals · 2025-11-13 | Valtoco | $21 |
| Catalyst Pharmaceuticals | Meals · 2025-11-13 | Firdapse | $7 |
| Catalyst Pharmaceuticals | Meals · 2025-11-13 | Firdapse | $23 |
| Eisai | Meals · 2025-11-12 | Leqembi | $28 |
| Teva Pharmaceuticals USA | Meals · 2025-11-11 | Austedo Xr | $32 |
| Abbvie | Meals · 2025-10-31 | Qulipta | $15 |
| Lundbeck | Meals · 2025-10-27 | Vyepti | $26 |
| Catalyst Pharmaceuticals | Meals · 2025-10-21 | Firdapse | $12 |
| Catalyst Pharmaceuticals | Meals · 2025-10-21 | Firdapse | $10 |
| Janssen Biotech | Meals · 2025-10-20 | None | $36 |
| TG Therapeutics | Meals · 2025-10-13 | Briumvi | $21 |
| Ucb | Meals · 2025-10-08 | Nayzilam | $32 |
| Catalyst Pharmaceuticals | Meals · 2025-10-08 | Firdapse | $7 |
| Catalyst Pharmaceuticals | Meals · 2025-10-08 | Firdapse | $20 |
| Neurelis | Meals · 2025-09-30 | Valtoco | $26 |
| Eisai | Meals · 2025-09-29 | Leqembi | $24 |
| Alexion Pharmaceuticals | Meals · 2025-09-11 | Ultomiris | $30 |
| Biogen | Meals · 2025-09-08 | Tysabri | $19 |
| Catalyst Pharmaceuticals | Meals · 2025-09-08 | Firdapse | $19 |
| Catalyst Pharmaceuticals | Meals · 2025-08-28 | Firdapse | $7 |
| Catalyst Pharmaceuticals | Meals · 2025-08-28 | Firdapse | $19 |
| SK Life Science | Meals · 2025-08-26 | None | $15 |
| Genentech USA | Meals · 2025-08-25 | Ocrevus Zunovo | $17 |
| Pfizer | Meals · 2025-08-21 | Nurtec Odt | $26 |
| Eisai | Meals · 2025-08-19 | Leqembi | $21 |
| Neurelis | Meals · 2025-08-18 | Valtoco | $28 |
| Teva Pharmaceuticals USA | Meals · 2025-08-14 | Ajovy | $37 |
| TG Therapeutics | Meals · 2025-08-11 | Briumvi | $21 |
| Novartis Pharmaceuticals | Meals · 2025-08-07 | Kesimpta | $31 |
| CSL Behring | Meals · 2025-07-31 | Hizentra | $21 |
| Lundbeck | Meals · 2025-07-31 | Vyepti | $21 |
| Alexion Pharmaceuticals | Meals · 2025-07-30 | Ultomiris | $30 |
| Pfizer | Meals · 2025-07-23 | Nurtec Odt | $26 |
| Catalyst Pharmaceuticals | Meals · 2025-07-16 | Firdapse | $7 |
| Catalyst Pharmaceuticals | Meals · 2025-07-16 | Firdapse | $19 |
| Eisai | Meals · 2025-07-15 | Leqembi | $18 |
| Lilly USA | Meals · 2025-07-14 | Kisunla | $23 |
| Ucb | Meals · 2025-07-07 | Nayzilam | $15 |
| Neurocrine BioSciences | Meals · 2025-07-01 | Ingrezza | $37 |
| Janssen Biotech | Meals · 2025-06-26 | None | $25 |
| Pfizer | Meals · 2025-06-24 | Nurtec Odt | $25 |
| Catalyst Pharmaceuticals | Meals · 2025-06-16 | Firdapse | $38 |
| Teva Pharmaceuticals USA | Meals · 2025-05-29 | Ajovy | $26 |
| Alexion Pharmaceuticals | Meals · 2025-05-28 | Ultomiris | $22 |
| Pfizer | Meals · 2025-05-28 | Nurtec Odt | $21 |
| Neurelis | Meals · 2025-05-27 | Valtoco | $12 |
| CSL Behring | Meals · 2025-05-16 | Hizentra | $20 |
| Argenx US | Meals · 2025-05-14 | Vyvgart Hytrulo | $24 |
| Eisai | Meals · 2025-05-13 | Leqembi | $19 |
| Amneal Pharmaceuticals | Meals · 2025-05-09 | Rytary | $15 |
| Neurelis | Meals · 2025-05-08 | Valtoco | $29 |
| Lundbeck | Meals · 2025-05-05 | Vyepti | $29 |
| Catalyst Pharmaceuticals | Meals · 2025-04-07 | Firdapse | $26 |
| Alexion Pharmaceuticals | Meals · 2025-03-26 | Ultomiris | $27 |
| Teva Pharmaceuticals USA | Meals · 2025-03-26 | Ajovy | $27 |
| SK Life Science | Meals · 2025-03-20 | None | $25 |
| Pfizer | Meals · 2025-03-05 | Nurtec Odt | $22 |
| Lundbeck | Meals · 2025-03-05 | Vyepti | $25 |
| Eisai | Meals · 2025-02-27 | Leqembi | $21 |
| Genentech USA | Meals · 2025-02-25 | Ocrevus Zunovo | $33 |
| Abbvie | Meals · 2025-02-05 | Ubrelvy | $19 |
| Alexion Pharmaceuticals | Meals · 2025-01-29 | Ultomiris | $32 |
| Catalyst Pharmaceuticals | Meals · 2025-01-29 | Fycompa | $6 |
| Catalyst Pharmaceuticals | Meals · 2025-01-29 | Fycompa | $17 |
| Ucb | Meals · 2025-01-22 | Briviact | $26 |
| Eisai | Meals · 2025-01-16 | Leqembi | $31 |
| Lilly USA | Meals · 2025-01-15 | Kisunla | $31 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,667
| Catalyst Pharmaceuticals | Fycompa | $354 | 20 payments
|
| Ucb | Briviact | $283 | 16 payments
|
| Abbvie | Qulipta | $228 | 12 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $219 | 9 payments
|
| Celgene | Zeposia | $207 | 13 payments
|
| Neurelis | Valtoco | $204 | 8 payments
|
| Alexion Pharmaceuticals | Ultomiris | $187 | 7 payments
|
| Eisai | Leqembi | $155 | 8 payments
|
| Lilly USA | Kisunla | $121 | 5 payments
|
| Lundbeck | Vyepti | $108 | 4 payments
|
| Neurocrine Biosciences | Ingrezza | $104 | 4 payments
|
| Pfizer | Nurtec Odt | $83 | 4 payments
|
| SK Life Science | None | $63 | 3 payments
|
| Biogen | Tysabri | $62 | 3 payments
|
| Novartis Pharmaceuticals | Kesimpta | $57 | 2 payments
|
| Argenx US | Vyvgart Hytrulo | $42 | 2 payments
|
| CSL Behring | Hizentra | $37 | 1 payment
|
| Mitsubishi Tanabe Pharma America | Radicava | $31 | 2 payments
|
| Amneal Pharmaceuticals | Rytary | $30 | 1 payment
|
| Kyowa Kirin | Nourianz | $26 | 1 payment
|
| Acorda Therapeutics | Inbrija | $22 | 1 payment
|
| Sumitomo Pharma America | Aptiom | $22 | 1 payment
|
| Otsuka America Pharmaceutical | Nuedexta | $20 | 1 payment
|
2023: $1,798
| Abbvie | Qulipta | $221 | 8 payments
|
| Catalyst Pharmaceuticals | Fycompa | $186 | 10 payments
|
| Sumitomo Pharma America | Aptiom | $174 | 11 payments
|
| Lundbeck | Vyepti | $143 | 6 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $138 | 6 payments
|
| SK Life Science | None | $132 | 6 payments
|
| Eisai | Fycompa | $104 | 5 payments
|
| Biogen | Tysabri | $85 | 4 payments
|
| Lilly USA | Amyvid | $74 | 3 payments
|
| Amneal Pharmaceuticals | Rytary | $72 | 3 payments
|
| Argenx US | Vyvgart Hytrulo | $71 | 4 payments
|
| Acorda Therapeutics | Inbrija | $70 | 4 payments
|
| Mitsubishi Tanabe Pharma America | Radicava | $60 | 2 payments
|
| Ucb | Briviact | $59 | 3 payments
|
| Pfizer | Nurtec Odt | $54 | 3 payments
|
| Celgene | Zeposia | $37 | 2 payments
|
| Genentech USA | Ocrevus | $37 | 2 payments
|
| Octapharma USA | Panzyga | $29 | 1 payment
|
| Janssen Pharmaceuticals | Ponvory | $19 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $19 | 1 payment
|
| Otsuka America Pharmaceutical | Nuedexta | $14 | 1 payment
|
2022: $1,552
| SK Life Science | None | $234 | 12 payments
|
| Eisai | Fycompa | $225 | 13 payments
|
| Biogen | Tysabri | $179 | 8 payments
|
| Ucb | Briviact | $161 | 6 payments
|
| Abbvie | Ubrelvy | $136 | 11 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $120 | 6 payments
|
| Avanir Pharmaceuticals | Nuedexta | $89 | 4 payments
|
| Teva Pharmaceuticals USA | Ajovy | $81 | 4 payments
|
| Kyowa Kirin | Nourianz | $57 | 3 payments
|
| Celgene | Zeposia | $43 | 3 payments
|
| Lundbeck | Vyepti | $43 | 2 payments
|
| Genentech USA | Ocrevus | $33 | 1 payment
|
| Janssen Pharmaceuticals | Ponvory | $31 | 2 payments
|
| Allergan | Botox | $30 | 1 payment
|
| Mitsubishi Tanabe Pharma America | Radicava | $25 | 1 payment
|
| Avion Pharmaceuticals | Dhivy | $24 | 1 payment
|
| Amgen | Aimovig | $21 | 1 payment
|
| Lilly USA | Emgality | $20 | 1 payment
|
2021: $2,246
| Teva Pharmaceuticals USA | Ajovy | $349 | 13 payments
|
| Eisai | Fycompa | $315 | 42 payments
|
| Ucb | Briviact | $277 | 12 payments
|
| Biogen | Tysabri | $228 | 14 payments
|
| AbbVie | Ubrelvy | $197 | 21 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $103 | 6 payments
|
| Lundbeck | Vyepti | $97 | 5 payments
|
| Avanir Pharmaceuticals | Nuedexta | $86 | 4 payments
|
| Neurocrine Biosciences | Ingrezza | $85 | 3 payments
|
| SK Life Science | None | $84 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $63 | 3 payments
|
| Allergan | Botox | $54 | 4 payments
|
| Amgen | Aimovig | $41 | 2 payments
|
| Kyowa Kirin | Nourianz | $41 | 2 payments
|
| Celgene | Zeposia | $37 | 3 payments
|
| Ge Healthcare | None | $28 | 1 payment
|
| Mitsubishi Tanabe Pharma America | Radicava | $24 | 1 payment
|
| Genentech USA | Ocrevus | $24 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $24 | 1 payment
|
| Merz Pharmaceuticals | Xeomin | $22 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $20 | 1 payment
|
| Adamas Pharmaceuticals | Gocovri | $19 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $17 | 1 payment
|
| Xeris Pharmaceuticals | Keveyis | $12 | 1 payment
|
2020: $994
| Allergan | Botox | $153 | 12 payments
|
| Avanir Pharmaceuticals | Nuedexta | $149 | 9 payments
|
| Eisai | Fycompa | $127 | 10 payments
|
| Ucb | Vimpat | $125 | 7 payments
|
| Teva Pharmaceuticals USA | Ajovy | $117 | 7 payments
|
| Amgen | Aimovig | $62 | 2 payments
|
| Kyowa Kirin | Nourianz | $47 | 3 payments
|
| Adamas Pharmaceuticals | Gocovri | $32 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $30 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $26 | 2 payments
|
| Genentech USA | Ocrevus | $23 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $22 | 1 payment
|
| Amneal Pharmaceuticals | Rytary | $21 | 1 payment
|
| Celgene | Zeposia | $19 | 1 payment
|
| Portola Pharmaceuticals | Andexxa | $15 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $15 | 1 payment
|
| Medtronic Vascular | Reveal Linq | $13 | 1 payment
|
2019: $1,212
| Ucb | Vimpat | $264 | 14 payments
|
| Biogen | Tysabri | $115 | 5 payments
|
| Eisai | Fycompa | $110 | 10 payments
|
| Avanir Pharmaceuticals | Nuedexta | $102 | 7 payments
|
| Genentech USA | Ocrevus | $74 | 3 payments
|
| Alexion Pharmaceuticals | Soliris | $65 | 4 payments
|
| Lilly USA | Emgality | $64 | 4 payments
|
| Akcea Therapeutics | Tegsedi | $61 | 1 payment
|
| Greenwich Biosciences | Epidiolex | $49 | 1 payment
|
| Lundbeck | Northera | $41 | 2 payments
|
| Amgen | Aimovig | $40 | 2 payments
|
| Adamas Pharmaceuticals | Gocovri | $36 | 2 payments
|
| Genzyme | Aubagio | $34 | 1 payment
|
| US WorldMeds | Xadago | $28 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $28 | 1 payment
|
| Arbor Pharmaceuticals | Horizant | $23 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $19 | 1 payment
|
| Acorda Therapeutics | Inbrija | $17 | 1 payment
|
| Novartis Pharmaceuticals | Aimovig | $16 | 1 payment
|
| Kyowa Kirin | Nourianz | $14 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $12 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 0.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1720145147
- Licence
- CA A066854
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- 2516 Samaritan Dr, Suite K, San Jose, CA, 95124
- NPI first listed
- 2007-01-03
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.